Bristol-Myers wins FDA nod for Opdivo lung cancer indication
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
bovnews16h
Why Did Bristol-Myers Squibb Co (BMY) Stock See 34.20% Surge in the Last 90 Days?
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
stocknews16h
3 Pharmaceutical Stocks That Could Lead the Next Drug Revolution
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
Zacks.com on MSN13h
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
2 Passive Income Stocks to Load Up On in October
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia
AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...
Reuters11h
United States
Dockworkers and port operators reached a wage deal to settle the industry's biggest work stoppage in nearly half a century, but clearing the cargo backlog will take time.